Literature DB >> 10755240

Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group.

D J Diekema1, M A Pfaller, R N Jones, G V Doern, K C Kugler, M L Beach, H S Sader.   

Abstract

From January through June of 1998, 4579 bloodstream infections (BSI) due to bacterial pathogens were reported from SENTRY hospitals in Canada, the USA and Latin America. Staphylococcus aureus, Escherichia coli, and coagulase-negative staphylococcus (CoNS) were the most common pathogens, together accounting for 55.2% of all BSI during this time period. Compared with the 5794 BSI reported from SENTRY from January through June of 1997, no major change was seen in the frequencies of occurrence of the most common bacterial causes of BSI. Between 1997 and 1998, the major change in antimicrobial resistance was an increase in oxacillin-resistance in both S. aureus and CoNS in all regions. These data demonstrate widespread antimicrobial resistance in Canada, Latin America and the USA, with a notable increase in oxacillin-resistance among staphylococci. Ongoing surveillance remains essential, and will enhance efforts to limit the scope of this worldwide problem.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755240     DOI: 10.1016/s0924-8579(99)00131-4

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  32 in total

1.  Potencies of newer fluoroquinolones against Viridans group Streptococciisolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): beyond Canada!

Authors:  R N Jones; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Three-year assessment of methicillin-resistant Staphylococcus aureus clones in Latin America from 1996 to 1998.

Authors:  M Aires De Sousa; M Miragaia; I S Sanches; S Avila; I Adamson; S T Casagrande; M C Brandileone; R Palacio; L Dell'Acqua; M Hortal; T Camou; A Rossi; M E Velazquez-Meza; G Echaniz-Aviles; F Solorzano-Santos; I Heitmann; H de Lencastre
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

3.  Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.

Authors:  Johan W Mouton; Anne Schmitt-Hoffmann; Stuart Shapiro; Norman Nashed; Nieko C Punt
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

4.  Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.

Authors:  Anton Leighton; Alice Bendix Gottlieb; Mary Beth Dorr; Daniela Jabes; Giorgio Mosconi; Claudia VanSaders; Edward J Mroszczak; Kathleen C M Campbell; Ellen Kelly
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

5.  Evaluation of the Accelerate Pheno System for Fast Identification and Antimicrobial Susceptibility Testing from Positive Blood Cultures in Bloodstream Infections Caused by Gram-Negative Pathogens.

Authors:  Matthias Marschal; Johanna Bachmaier; Ingo Autenrieth; Philipp Oberhettinger; Matthias Willmann; Silke Peter
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

Review 6.  Alternative folding pathways of the major porin OprF of Pseudomonas aeruginosa.

Authors:  Etsuko Sugawara; Keiji Nagano; Hiroshi Nikaido
Journal:  FEBS J       Date:  2012-02-10       Impact factor: 5.542

7.  The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia.

Authors:  Jack D Sobel
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.725

8.  Effects of rapid detection of bloodstream infections on length of hospitalization and hospital charges.

Authors:  S E Beekmann; D J Diekema; K C Chapin; G V Doern
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy.

Authors:  Richard P Wenzel; Daniel F Sahm; Clyde Thornsberry; Deborah C Draghi; Mark E Jones; James A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Regulatory Requirements for Staphylococcus aureus Nitric Oxide Resistance.

Authors:  Melinda R Grosser; Andy Weiss; Lindsey N Shaw; Anthony R Richardson
Journal:  J Bacteriol       Date:  2016-07-13       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.